AdAlta Ltd (ASX:1AD) is a clinical-stage drug development company using its proprietary i-body technology platform to generate a promising new class of medicines, headquartered in Melbourne, Australia.
The company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics.